TY - JOUR
T1 - Depression
AU - Choe, Christine J.
AU - Emslie, Graham J.
AU - Mayes, Taryn L.
N1 - Funding Information:
Disclosures: Dr Graham Emslie discloses that he received research/grant support from the National Institute of Mental Health ; BioMarin Pharmaceutical Inc; Eli Lilly and Company; Forest Laboratories , Inc; and GlaxoSmithKline , and is a consultant for Biobehavioral Diagnostics, Inc; Bristol-Myers Squibb; Eli Lilly and Company; INC Research LLC; Lundbeck; Pfizer Inc; Seaside Therapeutics, Inc; Shire; and Valeant. Dr Choe and Ms. Mayes have no financial relationships to disclose.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 2012/10
Y1 - 2012/10
N2 - This article reviews the assessment and treatment for depression in children and adolescents, emphasizing the implementation of evidence-based treatments into clinical care. Past trials of antidepressant medications are reviewed, as well as the clinical use of antidepressants and pharmacologic strategies for refractory illness or in the context of comorbid conditions. Clinicians who treat youth now have a body of empiric research to help guide treatment decisions; however, personalized treatment based on associated symptoms, comorbid conditions, contextual factors, and psychiatric history is essential. Further research is needed in the pharmacologic treatment of depressed youth, including expanding the study of non-SSRI antidepressants, augmentation and adjunctive strategies, and treatment in patients with comorbid conditions.
AB - This article reviews the assessment and treatment for depression in children and adolescents, emphasizing the implementation of evidence-based treatments into clinical care. Past trials of antidepressant medications are reviewed, as well as the clinical use of antidepressants and pharmacologic strategies for refractory illness or in the context of comorbid conditions. Clinicians who treat youth now have a body of empiric research to help guide treatment decisions; however, personalized treatment based on associated symptoms, comorbid conditions, contextual factors, and psychiatric history is essential. Further research is needed in the pharmacologic treatment of depressed youth, including expanding the study of non-SSRI antidepressants, augmentation and adjunctive strategies, and treatment in patients with comorbid conditions.
KW - Antidepression treatment
KW - Depression
KW - MDD
KW - Psychopharmacotherapy
KW - Youth depression
UR - http://www.scopus.com/inward/record.url?scp=84867060982&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84867060982&partnerID=8YFLogxK
U2 - 10.1016/j.chc.2012.07.002
DO - 10.1016/j.chc.2012.07.002
M3 - Review article
C2 - 23040903
AN - SCOPUS:84867060982
VL - 21
SP - 807
EP - 829
JO - Child and Adolescent Psychiatric Clinics of North America
JF - Child and Adolescent Psychiatric Clinics of North America
SN - 1056-4993
IS - 4
ER -